Morgan Stanley analyst Mark Purcell lowered the firm’s price target on GSK to 1,535 GBp from 1,610 GBp and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- CureVac announces progress in Phase 2 COVID-19, Seasonal Flu programs
- GSK raises FY23 adjusted EPS growth view to 17%-20% from 14%-17%
- GSK reports Q3 adjusted EPS 50.4p, up 17% at CER
- GSK, Arrowhead announce deal with Janssen for rights to JNJ-3989
- 23andMe enters collaboration extension with data licensing agreement with GSK